The FDA approved Addyi (flibanserin), a libido-enhancing drug, in postmenopausal women under the age of 65. Experts explain what to expect, the side effects, and other alternatives.
On December 15, 2025, the U.S. FDA approved Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65.
Addyi was previously approved in 2015 for the treatment of HSDD in premenopausa... [6246 chars]